Vor Bio rises after partner RemeGen succeeds in Sjögren's disease study
Source: SeekingAlpha
2025-10-14 09:04:23 ET
More on Vor Biopharma, RemeGen Co., Ltd.
- Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise
- Vor Biopharma: Chinese Win Sets The Direction, But There Is Still Much Uncertainty
- Vor Biopharma registers 51M shares for resale linked to RemeGen deal and PIPE financing
- Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects
- Seeking Alpha’s Quant Rating on Vor Biopharma
Read the full article on Seeking Alpha
For further details see:
Vor Bio rises after partner RemeGen succeeds in Sjögren’s disease study
Remegen Co Ltd Reg Shs
NASDAQ: REGMF
REGMF Trading
0.0% G/L:
$10 Last:
1,500 Volume:
$10 Open:
